JP7854423B2 - Ｐｄ－ｌ１結合性作用剤およびその使用 - Google Patents

Ｐｄ－ｌ１結合性作用剤およびその使用

Info

Publication number
JP7854423B2
JP7854423B2 JP2023507633A JP2023507633A JP7854423B2 JP 7854423 B2 JP7854423 B2 JP 7854423B2 JP 2023507633 A JP2023507633 A JP 2023507633A JP 2023507633 A JP2023507633 A JP 2023507633A JP 7854423 B2 JP7854423 B2 JP 7854423B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536630A5 (enExample
JP2023536630A (ja
Inventor
ブライアン グレーザー，
ボニー ハマー，
シーマ カンタク，
Original Assignee
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2023536630A publication Critical patent/JP2023536630A/ja
Publication of JP2023536630A5 publication Critical patent/JP2023536630A5/ja
Application granted granted Critical
Publication of JP7854423B2 publication Critical patent/JP7854423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023507633A 2020-08-04 2021-08-03 Ｐｄ－ｌ１結合性作用剤およびその使用 Active JP7854423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061109P 2020-08-04 2020-08-04
US63/061,109 2020-08-04
PCT/US2021/044330 WO2022031695A1 (en) 2020-08-04 2021-08-03 Pd-l1 binding agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2023536630A JP2023536630A (ja) 2023-08-28
JP2023536630A5 JP2023536630A5 (enExample) 2024-08-08
JP7854423B2 true JP7854423B2 (ja) 2026-05-01

Family

ID=80118473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507633A Active JP7854423B2 (ja) 2020-08-04 2021-08-03 Ｐｄ－ｌ１結合性作用剤およびその使用

Country Status (7)

Country Link
US (1) US12679893B2 (enExample)
EP (1) EP4192884A4 (enExample)
JP (1) JP7854423B2 (enExample)
CN (1) CN116390951A (enExample)
AU (1) AU2021322183A1 (enExample)
CA (1) CA3187850A1 (enExample)
WO (1) WO2022031695A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021322114A1 (en) * 2020-08-04 2023-03-02 Exelixis, Inc. Multispecific binding agents and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019185035A1 (en) 2018-03-29 2019-10-03 Adagene Inc. Anti-pd-l1 antibodies and use thereof
JP2019528083A (ja) 2016-06-20 2019-10-10 カイマブ・リミテッド 抗ｐｄ−ｌ１抗体
JP2019532013A (ja) 2016-06-29 2019-11-07 チェックポイント セラピューティクス，インコーポレイテッド Ｐｄ−ｌ１特異的抗体およびそれを使用する方法
JP2020511133A (ja) 2017-03-09 2020-04-16 ゲンマブ エー／エス Ｐｄ−ｌ１に対する抗体
JP2020517239A (ja) 2017-04-18 2020-06-18 アール−ファーム・オーバーシーズ・インコーポレイテッドＲ−Ｐｈａｒｍ Ｏｖｅｒｓｅａｓ， Ｉｎｃ． 抗ｐｄ−ｌ１抗体とその使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362325B2 (en) 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
MX2011000501A (es) * 2008-07-18 2011-05-23 Squibb Bristol Myers Co Composiciones monovalentes para union a cd28 y metodos de uso.
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
MX2014001238A (es) * 2011-08-05 2014-09-22 Genentech Inc Anticuerpos contra poliubiquitina y métodos de uso.
MX2017001946A (es) * 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
JP7080213B2 (ja) * 2016-03-23 2022-06-03 スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド 新規抗ｐｄ－ｌ１抗体
US20190106494A1 (en) * 2016-06-13 2019-04-11 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
AU2018236272B2 (en) * 2017-03-15 2022-03-31 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
EP3672634A1 (en) * 2017-08-24 2020-07-01 Invenra, Inc. Multivalent receptor-clustering agonist antibody constructs
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
US12110332B2 (en) 2017-11-20 2024-10-08 Taizhou Mabtech Pharmaceutical Co., Ltd. Bifunctional fusion protein targeting CD47 and PD-L1
CA3084626A1 (en) 2017-12-04 2019-06-13 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
KR102845020B1 (ko) * 2017-12-28 2025-08-12 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
WO2019179434A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules
GB2596411B (en) 2018-10-29 2023-09-20 Tigatx Inc Compositions and methods comprising IgA antibody constructs
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2021322114A1 (en) 2020-08-04 2023-03-02 Exelixis, Inc. Multispecific binding agents and uses thereof
EP4475886A4 (en) 2022-02-09 2026-03-18 Exelixis Inc MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528083A (ja) 2016-06-20 2019-10-10 カイマブ・リミテッド 抗ｐｄ−ｌ１抗体
JP2019532013A (ja) 2016-06-29 2019-11-07 チェックポイント セラピューティクス，インコーポレイテッド Ｐｄ−ｌ１特異的抗体およびそれを使用する方法
JP2020511133A (ja) 2017-03-09 2020-04-16 ゲンマブ エー／エス Ｐｄ−ｌ１に対する抗体
JP2020517239A (ja) 2017-04-18 2020-06-18 アール−ファーム・オーバーシーズ・インコーポレイテッドＲ−Ｐｈａｒｍ Ｏｖｅｒｓｅａｓ， Ｉｎｃ． 抗ｐｄ−ｌ１抗体とその使用
WO2019185035A1 (en) 2018-03-29 2019-10-03 Adagene Inc. Anti-pd-l1 antibodies and use thereof

Also Published As

Publication number Publication date
US20230303699A1 (en) 2023-09-28
CN116390951A (zh) 2023-07-04
EP4192884A1 (en) 2023-06-14
WO2022031695A1 (en) 2022-02-10
CA3187850A1 (en) 2022-02-10
AU2021322183A1 (en) 2023-03-02
US12679893B2 (en) 2026-07-14
JP2023536630A (ja) 2023-08-28
EP4192884A4 (en) 2025-04-09

Similar Documents

Publication Publication Date Title
JP7133043B2 (ja) Ｄｌｌ３－ｃｄ３二重特異性抗体
JP7840312B2 (ja) 多重特異性結合性作用剤およびその使用
TW202210514A (zh) 針對tigit的抗體
WO2017084495A1 (zh) Pd-l1抗体、其抗原结合片段及其医药用途
US20250197502A1 (en) Multispecific binding agents and uses thereof
US20250326858A1 (en) 5t4 binding agents and uses thereof
US20230357391A1 (en) Cd47 binding agents and uses thereof
US20230303699A1 (en) Pd-l1 binding agents and uses thereof
CN118974098A (zh) 多重特异性结合剂及其用途
KR20260041817A (ko) 인터루킨-13 수용체 소단위 알파-2 결합제 및 이의 용도
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
HK1258783B (en) Cell injury inducing therapeutic drug for use in cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260420

R150 Certificate of patent or registration of utility model

Ref document number: 7854423

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150